Daratumumab-Based Triplet Therapy Shows Benefits for Relapsed/Refractory Multiple Myeloma
Results from a recent real-world analysis suggest possible benefits with early use of daratumumab-based t...
Read moreResearch & Access Updates
Cancer deaths must not be a side effect of the pandemic: delays in cancer diagnosis and treatment could cause thousands to suffer and die prematurely
Cancer Action Now was launch on May 24, an alliance of 28 health care organizations, which includes Myelo...
Read moreLetter to Federal Minister of Health regarding PMPRB amendments
Myeloma Canada, along with 24 signatories, wrote a letter to the Federal Health Minister, Jean-Yves Duclo...
Read moreCanCertainty Coalition Holds Ontario Government to Account
This past month along with the CANcertainty coalition, Myeloma Canada continued to advocate for the needs...
Read moreOptimizing Diagnosis in Canadian Cancer Care
On Feb 15, All.Can Canada launched a new report which highlights where improvements are needed in cancer...
Read moreCADTH Therapeutic Review of Multiple Myeloma Unique in Many Aspects
The CADTH Therapeutic Review of treatments for transplant-ineligible multiple myeloma patients represents...
Read more